vivo PC3 xenograft model in nude mice, inhibiting the growth of the tumors by about 51% compared to the control group.
Conclusions: These results suggest that S0154 and S0161 have anticancer and antimetastasis effects in prostate cancer cells both in vitro and in vivo, supporting their further development as potential therapeutic agents for prostate cancer.
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| INTRODUCTION
Human cancers pose serious public health and socio-economic threats worldwide, with increasing cancer incidence and mortality rates. In fact, it has been reported that about 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide. 1 Prostate cancer is the most frequently diagnosed cancer among men in developed countries. [1] [2] [3] Although most prostate cancer patients are initially responsive to androgen deprivation therapy, the response is frequently transient, and the majority of patients eventually progress to castration-resistant prostate cancer (CRPC). Chemotherapy has played a pivotal role in the setting of metastatic CRPC (mCRPC). However, despite the survival benefits afforded by taxanes, docetaxel, and cabazitaxel, the increases in survival due to these agents are modest, the side effects are often intolerable, and the development of resistance is common. It is therefore crucial to identify new, more effective, and less toxic agents to treat prostate cancer.
Voltage-gated ion channels, classically associated with impulse conduction in excitable cells, are also found in a variety of epithelial cell types, where their functions are not well known. Abnormal expression of ion channels was reported to be related to the adhesion, proliferation, apoptosis, migration, invasion, and metastasis of cells, particularly during cancer progression [3] [4] [5] [6] [7] [8] Consistent with a role for these molecules in cell signaling, channel proteins can form macromolecular complexes with growth factors and cell adhesion and other signaling molecules. Voltage-gated ion channels have been considered new targets for cancer therapy. 9, 10 The voltage-gated sodium channels (VGSCs), comprising nine α subunits (Nav1.1-Nav1.9, encoded by genes SCN1A-SCN11A), and four β subunits (β1-β4, encoded by genes SCN1B-SCN4B), are involved in many human malignancies, including prostate, 11, 12 breast, 13, 14 cervical, 15, 16 ovarian, 17 lung, 18, 19 and colon cancer. 20, 21 Agonism of the VGSCs can potentiate the metastatic ability of prostate cancer cells 22 and it was previously demonstrated that eicosapentaenoic acid, a VGSCs blocker, inhibited the invasiveness of prostate cancer cells. 23 The present study investigated the effects of novel synthetic sodium channel blockers (SCBs) on the viability of three prostate cancer cell lines. We further examined the impact of these compounds on the in vitro apoptosis, cell cycle, glucose uptake, intracellular sodium concentration, sodium ion-related protein expression, and the migration and invasion of human prostate cancer cells after treatment with the compounds. We also investigated the effects of the SCBs on prostate cancer growth in vivo using a prostate cancer xenograft model in BALB/c nude mice.
| MATERIALS AND METHODS

| Synthesis of compounds
Novel synthetic sodium channels blockers (SCBs) were generated in one of our laboratories (L.Y. supplemented to meet special nutritional requirements as reported in a previous study. 24 All cell culture media contained 10% fetal bovine serum (FBS, Hyclone). Cells were incubated in a stable, humidified environment at 37°C with 5% CO 2 and were passaged every 2-3 days when they became confluent. 
| Cell survival assay
| Cell proliferation
Cell proliferation was determined using a CFDA-SE probe (Beyotime). The results were determined by flow cytometry. 
| Wound-healing assay
To assess cell migration, PC3 cells were seeded into six-well plates, and their migration was assessed using the wound-healing assay. 25 When the cells reached at least 90% confluence, the cell layer was scratched with a 10 μL sterile micropipette tip, and each well was washed with PBS three times to remove cell debris. Subsequently, 10 μmol/L S0154 or S0161 was added to cells, and the migration of the PC3 was observed under an inverted microscope (Zeiss) at 0, 6, 12, and 24 h.
| Western blotting analysis
Western blotting was performed to detect the expression of various proteins in PC3 cells. The cells were plated onto six-well plates and treated with various concentrations of S0154, S0161, or DMSO for 24 h. The total proteins from the cells were extracted using ice cold RIPA buffer (BestBio) and the concentrations of proteins were determined using a BCA Protein Assay Kit (Beyotime). Equal amounts of proteins were added on 8-12%
SDS-PAGE gels and these proteins were transferred to PVDF membranes.
The membranes were then blocked with 5% skim milk for 4 h and incubated with specific antibodies to the proteins of interest overnight at 4°C with gentle shaking. The following day, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody for 2 h, and exposed to film in a darkroom. We monitored the body weight and tumor size every 3 days to assess the physical condition and tumor growth of the mice. The tumor size was measured using Vernier calipers and was calculated with the formula: length × width 2 /2. After 3 weeks, the three groups mice were sacrificed and the tumors were removed, weighed, and photographed.
| Tumor xenograft study
| Statistical analysis
All of the measure data were expressed as the means ± standard deviations (SD), and statistical analyses were performed using SPSS 17.0. A one-way ANOVA was used to analyze the statistical significance of differences between experimental and control groups when data had a normal distribution and homogeneity of variance. Differences were considered to be statistically significant for values of P < 0.05.
3 | RESULTS
| The effects of SCBs on the viability of three prostate cancer cell lines
As shown in Table 1 
| S0154 and S0161 block sodium ion effusion in PC3 cells
Sodium indicator assays were used to detect the intracellular levels of sodium in PC3 cells treated with S0154 or S0161 for 30 min. The 10 μmol/L concentration of S0154 or S0161 significantly increased the intracellular levels of sodium, which indicated that sodium ion effusion was blocked by both compounds (Figure 2A ). Of note, the 5 μmol/L concentration of S0154 or S0161 also blocked the sodium ion effusion, but the block was not significant. Subunit Nav1.7 was more sensitive to treatment with the SCBs than Nav1.6 ( Figure 2B ).
We evaluated the protein expression of Nav1.6 and Nav1.7 in PC3 cells exposed to S0154 or S0161 for 24 h. The results showed that S0154 and S0161 both down-regulated the protein expression of Nav1.6 and Nav1.7 ( Figure 2B ). Subunit Nav1.6 was more sensitive to treatment with S0154 than S0161, while Nav1.6 was more sensitive to treatment with S0161 than S0154.
We further evaluated the protein degradation of Nav1.6 and Nav1.7 after pre-treating the cells with S0154 and S0161 for 8 h, followed by treatment with cycloheximide (CHX), an inhibitor of protein synthesis, for various times. As shown in Figure 2C , S0154 and S0161 shortened the half-lives of Nav1.6 and Nav1.7 and promoted their degradation in PC3 cells. S0135  >50  >50  >50  >50  >50  >50  >50  >50  >50   S0142  >50  >50  >50  >50  >50  >50  >50  >50  >50   S0143  >50  >50  >50  >50  >50  >50  >50  >50  >50   S0152  >50  >50  >50 The DU145 LnCaP and PC3 cells were treated with increasing doses of the SCBs for 72 h, then calculated IC20, IC50, and IC80, respectively. n = 3 independent experiments. Bold signifies highlighting effective drugs (s0154 and s0161).
FIGURE 2
Effects of S0154 or S0161 on sodium ion effusion and the protein expressionof sodium channels subunits. A, After being treated with 5 and 10 μmol/L concentrations of S0154 and S0161 for 30 min, the cells' intracellular concentration of free sodium ion (Na + ) was checked using a sodium indicator assay. B, Example immunoblots of PC3 cells treated with various concentrations of S0154 and S0161 for 24 h. C, After being pre-treated with 10 µM S0154 and S0161 for 8 h, the cells were exposed to 15 μg/mL CHX for various lengths of time. n = 3 independent experiments. *P<0.05 versus the control. [Color figure can be viewed at wileyonlinelibrary.com] 3.3 | S0154 and S0161 decrease the glucose uptake and suppress the proliferation of PC3 cells Glucose transport is driven by an inward sodium gradient. 26 Pioneering studies by Warburg et al established that tumors have an increased demand for glucose to fuel ATP synthesis by aerobic glycolysis. 27 Tumor proliferation and metastasis demand increased glucose consumption (and intake) because of the high rates of glycolysis.
Thus, a change in sodium uptake would affect the glucose uptake, thereby inhibiting proliferation. The ability of cells to internalize extracellular glucose can be assessed by using fluid-phase tracer FITCglucose. Using this method, we found that 5 and 10 μmol/L of S0154 or S0161 significantly decreased the glucose uptake of PC3 cells ( Figures 3A and 3B ), and the cell proliferation was significantly suppressed by 10 and 20 μmol/L of S0154 or S0161 ( Figure 3C ), with S0161 leading to stronger suppression.
| S0154 and S0161 induce G2/M cell cycle arrest in PC3 cells
The results of a cell cycle analysis indicated that treatment with either To further assess the effects of S0154 and S0161 on the cell cycle, we detected the expression of two key G2/M phase proteins, CDK1
and Cyclin B1. Treatment with 10, 15, and 20 μmol/L of S0154 or S0161 down-regulated the expression levels of CDK1 and Cyclin B1
( Figures 4D and 4H ). These results indicated that the induction of cell cycle arrest may be a major mechanism by which S0154 and S0161 exert anticancer effects.
| Effects of S0154 and S0161 on the apoptosis of PC3 cells
As shown in Figures 5A and 5B, the apoptosis index of the PC3 cells slightly increased after treatment with S0154 and S0161 for 48 h. There was significant increase in apoptosis following exposure to 20 μmol/L of S0154, however, there was no significant increase in apoptosis induced by exposure to 20 μmol/L of S0161.
Considering that the IC 50 values were 10.51 μmol/L for S0154 and 5.07 μmol/L for S0161, the induction of apoptosis does not appear to be a major mechanism underlying the anticancer effects of these compounds. 
| S0154 and S0161 inhibit the invasion of PC3 cells
To investigate whether S0154 and S0161 could inhibit prostate cancer cell metastasis, we examined their effects on cell migration and invasion.
S0154 or S0161 inhibited the invasion of PC3 cells in a dose-dependent manner ( Figure 6A ). As illustrated in Figure 6B , both S0154 and S0161
(beginning at 2.5 μmol/L) significantly decreased the number of PC3 cells that invaded the Matrigel layer. Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of the extracellular matrix (ECM) during cancer metastasis. 28 The expression levels of MMPs, MMP-2, and MMP-9 were assessed after SCBs treatment, and are shown in Figure 6C . S0154 or S0161 down-regulated the expression of both MMP-2 and MMP-9 at 10 μmol/L. Moreover, the protein expression levels of MMP2 and MMP9 were noted to be downregulated beginning at 2.5 μmol/L of S0154 and S0161, respectively.
Moreover, in a wound-healing assay, S0154 and S0161 slightly (but not significantly) inhibited PC3 cell migration after 12 h treatment (Figure 7 ).
| S0161 decreases the growth of PC3 xenograft tumors
To further assess the anti-tumor activity of S0154 and S0161 in vivo, we established a PC3 xenograft tumor model. Nude mice bearing PC3 xenograft tumors were randomly divided into a control group, S0154 group, and S0161 group for corresponding treatment. The body weight and tumor size of the mice were monitored every 3 days, and the measured data are shown in Figures 8A and 8B . There were no significant differences in the body weights of the mice between the control and experimental groups, indicating that exposure to S0154 or S0161 for the treatment periods did not lead to over toxicity in the nude mice ( Figure 8A ). The mice treated with 5 mg/kg bodyweight of either S0154 or S0161 showed slower growth of the xenograft tumors than the control group. There was a significant difference in the tumors weights between the control and S0161 groups ( Figure 8C ). On day 21, it was noted that treatment with 5 mg/kg of S0161 had significantly inhibited tumor growth by about 51% compared with the control group (P = 0.003) ( Figure 8D ). There was no significant difference in the tumor weights between the 5 mg/kg S0154 treatment group and the control group (P = 0.124) ( Figure 8D ). Nav1.5 is a key regulator that controls colon cancer invasion. 21 Hernandez-Plata similarly showed that overexpression of Nav1.6 is associated with the invasion capacity of human cervical cancer. 16 Functional expression of Nav1.7 was associated with strong metastatic potential in prostate cancer in vitro, 11 and the protein was also necessary for the EGF-mediated invasion of human non-small cell lung cancer cells. 18 The β1 subunit mediates the outgrowth of breast cancer cells and promotes tumor growth and metastasis. 13 A previous study showed that agonism of VGSCs can potentiate the metastatic behavior of prostate cancer cells. 22 Resveratrol, a VGSC blocker, inhibited voltage-gated Na + channel activity and metastatic cell behaviors. 32 Eicosapentaenoicacid has also been reported to directly Tumor proliferation and metastasis increase the cellular glucose consumption because of the high rate of glycolysis. 27 The results of sodium indicator and glucose uptake assays showed that both S0154 and S0161 significantly increased the level of intracellular sodium, and decreased the glucose uptake of PC3 cells. These results indicated that the sodium channel was blocked by S0154 and S0161. Subunits Nav1.6 and Nav1.7 were previously shown to be significantly up-regulated in prostate cancer cell lines, and may be potential diagnostic markers and/or therapeutic targets. 33 Western blotting showed that S0161 down-regulated the expression levels of
FIGURE 6
Effects of S0154 and S0161 on the invasion of PC3 cells. A, PC3 cells were exposed to 0 (solvent control), 2.5, 5, or 10 μmol/L of S0154 or S0161 for 24 h and the invasion was assessed by a transwell assay. B, S0154 and S0161 significantly decreased the number of invasive PC3 cells, as determined by counting nine high-power microscopic fields for each sample. C, PC3 cells were exposed to various concentrations of S0154 or S0161 for 24 h, then target proteins (MMP-2 and MMP-9) were examined by Western blotting. Data points represent the mean ± standard error for three independent experiments. *P < 0.05 versus the control. [Color figure can be viewed at wileyonlinelibrary.com] both Nav1.6 and Nav1.7 proteins, while S0154 decreased the expression of Nav1.6. These results indicate that S0154 and S0161
may target different subunits of VGSCs to exert their anticancer effects.
Metastasis is a major cause of death in cancer patients, largely because metastatic tumors are frequently resistant to conventional therapies and not amenable to surgery. Previous reports indicated that the expression of VGSCs is related to cancer cell metastasis. 8, 22 To detect whether S0154 and S0161 could affect the metastatic behavior of PC3 cells, we performed a wound-healing assay and transwell chamber assay, and assessed the expression levels of MMP-2 and MMP-9, two proteins associated with cancer metastasis. We found that the 2.5 μmol/L concentrations of both S0154 and S0161
obviously inhibited PC3 cells invasion. However, the compounds had limited effects on PC3 cell migration, perhaps due to the experimental conditions. Of note, the expression of MMP-2 protein was decreased by both S0154 and S0161, and MMP-9 expression was also down-regulated by S0161. These findings suggest that S0154 and S0161 can inhibit PC3 cell invasion, potentially decreasing metastasis.
In addition, we found that S0154 and S0161 could both decrease the growth of xenograft tumors compared to DMSO-treated controls.
The tumor growth of the S0161 group was significantly inhibited by about 51% compared to the control. Further in vivo studies, including studies of metastatic models, are warranted to demonstrate the potential of the compounds.
In summary, S0154 and S0161 were shown to have obvious anticancer and anti-metastasis effects in human PC3 prostate cancer cells. Although the detailed mechanisms underlying how S0154 and S0161 inhibit prostate cancer are unclear, both compounds exhibited strong potential as novel therapeutic VGSCs blockers.
| CONCLUSIONS
The present results suggest that S0154 and S0161 have anticancer and anti-metastasis effects in prostate cancer cells in vitro and in vivo, supporting their further development as potential anticancer and antimetastasis agents for the treatment of mCRPC. Effects of S0154 and S0161 on the migration of PC3 cells. Wound-healing assays were used to examine the effects of S0154 and S0161 on the migration of PC3 cells. The cells were grown to at least 90% confluence, and then were scratched to make a wound. The migration of PC3 cells treated with 10 μmol/L S0154 or S0161 was monitored for 0, 6, 12, and 24 h, and images obtained using an inverted microscope were compared to those of the control (solvent) group. [Color figure can be viewed at wileyonlinelibrary.com]
